Lung Cancer

Drug that targets RET fusion shows good responses in NSCLC and thyroid cancers

A novel drug designed to specifically target RET has shown high response rates and durable efficacy in patients with RET fusion positive lung and thyroid cancers. The results from two phase 1-2 trials of selpercatinib (formerly known as LOXO-292) just published in NEJM also show that it is well tolerated and has significant intracranial activity ...

Already a member?

Login to keep reading.

© 2021 the limbic